At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]
A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]
There are a number of men who have written on various listservs that they use DES (diethylstilbestrol) as a hormonal suppressant. Actually, the current standard of care calls for the use of the gonadotropin-releasing hormone (GnRH) agonists, leuprolide and goserelin for a hormone blockade. So, what is the actual role of DES and why isn’t [...]